Dr. Iryna M. Crescenze, MD

Dr. Crescenze practices at OSU Eye and Ear Institute in Columbus, Ohio.

Dr. Crescenze's NPI, 1942507322, was assigned on February 21, 2011. Dr. Crescenze graduated from Medical College Of Wisconsin in 2011. Dr. Crescenze holds Ohio license 35136762.

Dr. Crescenze's primary practice is OSU Eye and Ear Institute, at 915 Olentangy River Rd, Columbus, OH 43212 in Franklin County. The practice phone is (614) 293-8566.

Dr. Crescenze's primary practice is OSU Eye and Ear Institute in Columbus, Ohio. Dr. Crescenze is also affiliated with Ohio State University Hospital. The medical group on file is Ohio State University Physicians. Dmand AI also links Dr. Crescenze to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Crescenze practices, 3 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Crescenze's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Crescenze is licensed in Ohio.

CMS data shows 6,221 Medicare services from Dr. Crescenze across 18 procedure codes in 2024, for 205 Medicare patients. Medicare paid $72,106 for them. Every service was in an office.

CMS counts 205 Medicare patients who saw Dr. Crescenze in 2024. The largest group is 65 to 74, with 92 patients. 72% of them have high blood pressure, and 66% have high cholesterol. 25% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Crescenze's median patient age at 63, with 66% women.

In 2024, Dr. Crescenze wrote 762 Medicare Part D claims for 191 patients. 79% of them were for generic drugs. CMS names the drug for 668 of them, across 18 drugs with 11 or more claims each, at $81,679 in total drug cost. In 2023, CMS named 574 claims across 18 drugs.

Dr. Crescenze accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Crescenze as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 11 papers to Dr. Crescenze, published from 2016 to 2023. 2020 was the busiest year, with 4. The most frequent topics are Urinary Bladder, Neurogenic, Spinal Cord Injuries and Cystitis, Interstitial. Dr. Crescenze has published most often in Urology. Dr. Crescenze's most frequent co-authors are Sara Marie Lenherr, MD, Humphrey Odei Atiemo, MD and Mary Charleton, MD.

CMS Open Payments shows 38 general payments to Dr. Crescenze from 9 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 69% of the total. Boston Scientific Corporation paid the most, $1,797. It also lists 1 research payment totaling $2,096 in 2022.

Dr. Crescenze graduated from Medical College Of Wisconsin in 2011.